News | May 31, 2021
Multiple catalysts ahead for Cadila Healthcare: HDFC Securities
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Dr. Sharvil Patel cites the example of prescriptions being handed over to patients despite unavailability of enough stock of such medicines
MEK inhibitor compound (LNP3794) developed as part of its oncology pipeline had previously shown pre-clinical activity as a single agent as well as in combination
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
The company plans to enter the EU markets in FY22
Subscribe To Our Newsletter & Stay Updated
